Search

Your search keyword '"Shinji Takamatsu"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Shinji Takamatsu" Remove constraint Author: "Shinji Takamatsu"
104 results on '"Shinji Takamatsu"'

Search Results

1. The specific core fucose-binding lectin Pholiota squarrosa lectin (PhoSL) inhibits hepatitis B virus infection in vitro

2. Enterococcus spp. have higher fitness for survival, in a pH‐dependent manner, in pancreatic juice among duodenal bacterial flora

3. Transcription factor SP1 regulates haptoglobin fucosylation via induction of GDP-fucose transporter 1 in the hepatoma cell line HepG2

4. Vesicular Integral-Membrane Protein 36 Is Involved in the Selective Secretion of Fucosylated Proteins into Bile Duct-like Structures in HepG2 Cells

5. Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death

6. Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis

7. Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

8. Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study

9. Establishment of a novel 70K Mac-2 binding protein antibody through screening of fucosylation-related antibodies

10. Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells

12. Pholiota squarrosa lectin (PhoSL), a lectin binding to core-fucose specifically, inhibits HBV infection

13. Identification of fucosylated haptoglobin‐producing cells in pancreatic cancer tissue and its molecular mechanism

14. Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis

15. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain

16. Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis

17. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis

18. Branched-chain amino acids protect the liver from cirrhotic injury via suppression of activation of lipopolysaccharide-binding protein, toll-like receptor 4, and signal transducer and activator of transcription 3, as well as Enterococcus faecalis translocation

19. Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study

20. Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production

21. Core fucose is essential glycosylation for CD14-dependent Toll-like receptor 4 and Toll-like receptor 2 signalling in macrophages

22. Establishment of an antibody specific for cancer-associated haptoglobin: a possible implication of clinical investigation

23. Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis

24. Hepatic aberrant glycosylation byN-acetylglucosaminyltransferase V accelerates HDL assembly

25. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis

26. Identification of the epitope of 10-7G glycan antibody to recognize cancer-associated haptoglobin

27. Development of α-Gal-Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies

28. Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer

29. N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis

30. Ectopic expression ofN-acetylglucosaminyltransferase V accelerates hepatic triglyceride synthesis

31. Establishment of a novel lectin–antibody ELISA system to determine core-fucosylated haptoglobin

32. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer

33. Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer

34. Development of α1,6-fucosyltransferase inhibitors through the diversity-oriented syntheses of GDP-fucose mimics using the coupling between alkyne and sulfonyl azide

35. Identification of Sialylated Glycoproteins in Doxorubicin-Treated Hepatoma Cells with Glycoproteomic Analyses

36. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer

37. Identification of Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (ENPP3) as a Regulator of N-Acetylglucosaminyltransferase GnT-IX (GnT-Vb)

38. N-glycosylation modulates the membrane sub-domain distribution and activity of glucose transporter 2 in pancreatic beta cells

39. Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy

40. Roles of Fucosyltransferases in Cancer Phenotypes

41. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases

42. A glycoproteomic approach to identify novel glycomarkers for cancer stem cells

43. Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle

44. Physiological and glycomic characterization of N-acetylglucosaminyltransferase-IVa and -IVb double deficient mice

45. Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment

46. Glyco-redox, a link between oxidative stress and changes of glycans: Lessons from research on glutathione, reactive oxygen and nitrogen species to glycobiology

47. Ectopic expression of N-acetylglucosaminyltransferase V accelerates hepatic triglyceride synthesis

48. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers

49. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development

50. Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring

Catalog

Books, media, physical & digital resources